It recorded a net loss of $117.3 million. Diluted earnings per share were $2.29.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 31, 2026
|
FY 2025
Oct 31, 2025
|
FY 2024
Oct 31, 2024
|
FY 2023
Oct 31, 2023
|
|---|---|---|---|---|
| Research and development |
96
+30.0%
|
94
+146.6%
|
38
+132.8%
|
16
|
| Selling, general and administrative |
40
+49.0%
|
29
+19.6%
|
24
+149.8%
|
10
|
| Operating income |
-137
-35.1%
|
-123
-97.7%
|
-62
-139.1%
|
-26
|
| Interest income |
10
-6.6%
|
9
-9.5%
|
10
+832.2%
|
1
|
| Interest expense |
3
+2.3%
|
3
+7.0%
|
3
|
—
|
| Other non-operating income (expense) |
-0
+20.5%
|
-1
-403.5%
|
-0
+12.4%
|
-0
|
| Pretax income |
-131
-38.9%
|
-117
-112.7%
|
-55
+44.8%
|
-100
|
| Income tax |
-0
-196.3%
|
0
+100.0%
|
-0
-211.8%
|
0
|
| Net income |
-130
-37.6%
|
-117
-112.7%
|
-55
+44.8%
|
-100
|
| Basic EPS |
-2.02
-5.3%
|
2.29
+56.8%
|
1.46
-99.0%
|
151.22
|
| Diluted EPS |
-2.02
-5.3%
|
2.29
+56.8%
|
1.46
-99.0%
|
151.22
|
| Weighted average shares, basic |
64
+30.6%
|
51
+35.3%
|
38
+5355.1%
|
1
|
| Weighted average shares, diluted |
64
+30.6%
|
51
+35.3%
|
38
+5355.1%
|
1
|
| Other measures | ||||
| Depreciation and amortization |
1
+75.0%
|
0
+66.7%
|
0
+50.0%
|
0
|
| EBITDA |
-136
-35.0%
|
-123
-97.9%
|
-62
-139.7%
|
-26
|
| Interest coverage |
-44.51x
|
-41.14x
|
-22.26x
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.